Multidrug Efflux Systems in Helicobacter cinaedi
AbstractHelicobacter cinaedi causes infections, such as bacteremia, diarrhea and cellulitis in mainly immunocompromised patients. This pathogen is often problematic to analyze, and insufficient information is available, because it grows slowly and poorly in subculture under a microaerobic atmosphere. The first-choice therapy to eradicate H. cinaedi is antimicrobial chemotherapy; however, its use is linked to the development of resistance. Although we need to understand the antimicrobial resistance mechanisms of H. cinaedi, unfortunately, sufficient genetic tools for H. cinaedi have not yet been developed. In July 2012, the complete sequence of H. cinaedi strain PAGU 611, isolated from a case of human bacteremia, was announced. This strain possesses multidrug efflux systems, intrinsic antimicrobial resistance mechanisms and typical mutations in gyrA and the 23S rRNA gene, which are involved in acquired resistance to fluoroquinolones and macrolides, respectively. Here, we compare the organization and properties of the efflux systems of H. cinaedi with the multidrug efflux systems identified in other bacteria. View Full-Text
Share & Cite This Article
Morita, Y.; Tomida, J.; Kawamura, Y. Multidrug Efflux Systems in Helicobacter cinaedi. Antibiotics 2012, 1, 29-43.
Morita Y, Tomida J, Kawamura Y. Multidrug Efflux Systems in Helicobacter cinaedi. Antibiotics. 2012; 1(1):29-43.Chicago/Turabian Style
Morita, Yuji; Tomida, Junko; Kawamura, Yoshiaki. 2012. "Multidrug Efflux Systems in Helicobacter cinaedi." Antibiotics 1, no. 1: 29-43.